CEDARHURST, NY / ACCESSWIRE / May 8, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.
NIO Inc. (NYSE: NIO)
Investors Affected : Purchasers of American Depositary Shares between September 12, 2018 and March 5, 2019
A class action has commenced on behalf of certain shareholders in NIO Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) NIO would not be building its own manufacturing plant and would instead continue to rely on JAC Auto to manufacture its vehicles; (2) reductions in government subsidies for electric cars would materially impact NIO's sales; and (3) as a result, Defendants' statements about NIO's business, operations, and prospects were materially false and misleading at all relevant times.
Shareholders may find more information at https://kclasslaw.com/securities/nio-inc-loss-submission-form/?id=1443&from=1
Corbus Pharmaceuticals Holdings, Inc. (NASDAQGM: CRBP)
Investors Affected : November 14, 2016 - February 28, 2019
A class action has commenced on behalf of certain shareholders in Corbus Pharmaceuticals Holdings, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Corbus improperly changed the primary efficacy endpoint for the clinical study of its drug candidate, Lenabasum, after the results were unblinded to Corbus; (2) Corbus reported a one-sided p value, not the traditional two-sided p value normally reported in clinical trials, in an effort to conceal the fact that the study results did not have statistical significance; and (3) as a result, Corbus' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
Shareholders may find more information at https://kclasslaw.com/securities/corbus-pharmaceutical-holdings-inc-loss-submission-form/?id=1443&from=1
American Renal Associates Holdings, Inc. (NYSE: ARA)
Investors Affected : August 10, 2016 - March 27, 2019
A class action has commenced on behalf of certain shareholders in American Renal Associates Holdings, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) issues with American Renal's accounting process for revenue recognition, collections, and related matters would give rise to a U.S. Securities and Exchange Commission (''SEC'') investigation into the same, and increased regulatory scrutiny by the SEC; (2) financial statements for the fiscal years 2014, 2015, 2016 and 2017 contained in its Annual Reports for the years ended December 31, 2016 and 2017, and its condensed consolidated financial statements in quarterly reports from 2016 through 2018, were false and could not be relied upon; (3) American Renal had material weaknesses in its internal control over financial reporting; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://kclasslaw.com/securities/american-renal-associates-holdings-inc-loss-submission-form/?id=1443&from=1
Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock.
CONTACT:
Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 344
Cedarhurst, NY 11516
Email: dk@kclasslaw.com
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967
SOURCE: Kuznicki Law PLLC
View source version on accesswire.com:
https://www.accesswire.com/544775/FILING-DEADLINE-Kuznicki-Law-PLLC-Announces-Class-Actions-on-Behalf-of-Shareholders-of-NIO-CRBP-and-ARA
